Imaging proliferation in vivo with [F-18]FLT and positron emission tomography

被引：968

作者：

Shields, AF

Grierson, JR

Dohmen, BM

Machulla, HJ

Stayanoff, JC

Lawhorn-Crews, JM

Obradovich, JE

Muzik, O

Mangner, TJ

机构：

[1] Wayne State Univ, Detroit Med Ctr, Dept Med, Karmanos Canc Inst, Detroit, MI 48301 USA

[2] Wayne State Univ, Detroit Med Ctr, Dept Radiol, Karmanos Canc Inst, Detroit, MI 48301 USA

[3] Univ Washington, Dept Radiol, Imaging Res Lab, Seattle, WA 98195 USA

[4] Univ Tubingen, Dept Nucl Med, Tuebingen, Germany

[5] Oakland Vet Referral Serv, Bloomfield Hills, MI USA

来源：

NATURE MEDICINE | 1998年 / 4卷 / 11期

关键词：

D O I：

10.1038/3337

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Positron emission tomography (PET) is now regularly used in the diagnosis and staging of cancer. These uses and its ability to monitor treatment response would be aided by the development of imaging agents that can be used to measure tissue and tumor proliferation. We have developed and tested [F-18]FLT (3'-deoxy-3'-fluorothymidine); it is resistant to degradation, is retained in proliferating tissues by the action of thymidine kinase 1 (TK), and produces high-contrast images of normal marrow and tumors in canine and human subjects.

引用

页码：1334 / 1336

页数：3

共 20 条

[1] SYNTHESIS OF 2'-FLUORO-5-[C-11]-METHYL-1-BETA-D-ARABINOFURANOSYLURACIL ([C-11]-FMAU) - A POTENTIAL NUCLEOSIDE ANALOG FOR IN-VIVO STUDY OF CELLULAR PROLIFERATION WITH PET
CONTI, PS
ALAUDDIN, MM
FISSEKIS, JR
SCHMALL, B
WATANABE, KA
[J]. NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (06) : 783 - 789
[2] F-18-5-FLUOROURIDINE, A NEW PROBE FOR MEASURING THE PROLIFERATION OF TISSUE INVIVO
CRAWFORD, EJ
FRIEDKIN, M
WOLF, AP
FOWLER, JS
GALLAGHER, BM
LAMBRECHT, RM
MACGREGOR, RR
SHIUE, CY
WODINSKY, I
GOLDIN, A
[J]. ADVANCES IN ENZYME REGULATION, 1982, 20 : 3 - +
[3] Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
Findlay, M
Young, H
Cunningham, D
Iveson, A
Cronin, B
Hickish, T
Pratt, B
Husband, J
Flower, M
Ott, R
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) : 700 - 708
[4] RELATIONSHIP BETWEEN PLASMA-CONCENTRATIONS OF 3'-DEOXY-3'-FLUOROTHYMIDINE (ALOVUDINE) AND ANTIRETROVIRAL ACTIVITY IN 2 CONCENTRATION-CONTROLLED TRIALS
FLEXNER, C
VANDERHORST, C
JACOBSON, MA
POWDERLY, W
DUNCANSON, F
GANES, D
BARDITCHCROVO, PA
PETTY, BG
BARON, PA
ARMSTRONG, D
BRICMONT, P
KUYE, O
YACOBI, A
DESJARDINS, R
POLSKY, B
[J]. JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (06) : 1394 - 1403
[5] Grierson J. R., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P290
[6] Grierson John R., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P60
[7] HERHOLZ K, 1992, J NEURO-ONCOL, V12, P159
[8] COMPARISONS OF ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS ACTIVITIES, CELLULAR-TRANSPORT, AND PLASMA AND INTRACELLULAR PHARMACOKINETICS OF 3'-FLUORO-3'-DEOXYTHYMIDINE AND 3'-AZIDO-3'-DEOXYTHYMIDINE
KONG, XB
ZHU, QY
VIDAL, PM
WATANABE, KA
POLSKY, B
ARMSTRONG, D
OSTRANDER, M
LANG, SA
MUCHMORE, E
CHOU, TC
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) : 808 - 818
[9] KUBOTA R, 1992, J NUCL MED, V33, P1972
[10] NICOLAS F, 1995, DRUG METAB DISPOS, V23, P308

← 1 2 →